Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of June 29th – July 5th, 2020.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view full article.
The pandemic first hit the U.S. earlier this year. The cannabis industry was deemed as essential and legal sales nationwide soared. With a possible second wave of the virus underway, investors should look at companies such as Red White & Bloom (CSE: RWB) (OTCQX: TDRYD), which controls a dominant 22% share of the Michigan market and compared to its multi-state operator (MSO) peers, is trading at an extremely attractive valuation.
9. Patents for Psychedelics: “We Have the Potential to All Be Winners if We Do This Right”
Consider: In April, MindMed (NEO: MMED) (OTCQB: MMEDF) (FRA: BGHM), working with the University Hospital Basel’s Laboratory, in Basel, Switzerland in a deal to support clinical trials and secure exclusive patent rights, discovered and filed a patent in the U.S. preserving all worldwide rights for a neutralizer technology that can shorten or even stop the hallucinogenic effects of LSD in a therapy session.
READ FULL PSYCHEDELICS PATENTS ARTICLE
8. Cronos Group: Raymond James Sees US$4.10/Share Valuation Just for Ginkgos Partnership
Raymond James Has Created a Valuation Method Specific to Cannabinoid Biosynthesis
Raymond James recently upgraded Cronos Group (TSX: CRON) (NASDAQ: CRON) (FRA: 7CI) to an Outperform 2 rating as well as almost doubling their price target to C$13.52 / U$10. The justification behind this was that they believe Cronos’ partnership with Ginkgo Bioworks currently adds $1.54 billion or US$4.10 a share in value.
READ FULL CRONOS GROUP ARTICLE
7. Curaleaf Unveils Nationwide Expansion Plans for Select Brand
Curaleaf (CSE: CURA) (OTCQX: CURLF) announced the continued expansion of its line of Select brand into new markets including Maine, Massachusetts, Ohio and Florida between now and August 2020.
6. Health Canada: ‘Any Celebrity Affiliation with Cannabis Has Potential to be Non-Compliant’
Last week, Organigram (TSX: OGI) (NASDAQ: OGI) (FRA: 0OG) announced it was making adjustments to the Trailer Park Buds brand after discussions with the regulator. Other Canadian licensed producers (LPs) with celebrity ties include Canopy Growth (TSX: WEED) (NYSE: CGC) (FRA: 11L1) (Snoop Dogg’s Leafs by Snoop and Seth Rogen‘s Houseplant brand), Tilray (NASDAQ: TLRY) (FRA: 2HQ) (Marley Natural-branded vape cartridges) and Supreme Cannabis (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) (Wiz Khalifa’s Khalifa Kush).
READ FULL HEALTH CANADA ARTICLE
5. Better Cannabis Stock: Aphria vs. Canopy Growth
Which of These Struggling Pot Stocks Should You Buy?
Today, I’ll look at two of the top Pot Stocks in the industry — Aphria (TSX: APHA) (NYSE: APHA) (FRA: 10E) and Canopy Growth (TSX: WEED) (NYSE: CGC) (FRA: 11L1) — and assess which of these leading cannabis producers is the better stock to hold in your portfolio.
READ FULL APHA VS WEED ARTICLE
4. Can Cannabis 2.0 Products Boost Canopy Growth and Organigram in 2020?
While all marijuana companies ramped up production to grab the opportunities of this new market, Canopy Growth (TSX: WEED) (NYSE: CGC) (FRA: 11L1) and Organigram (TSX: OGI) (NASDAQ: OGI) (FRA: 0OG) have focused on providing the most innovative products to consumers.
READ FULL CANNABIS 2.0 ARTICLE
3. Psychedelics Outlook: A New Industry Emerges
The idea of investing in Psychedelics has captured the attention of the market, but what’s next for this exciting new segment?
READ FULL PSYCHEDELICS INVESTING ARTICLE
2. The 3 Marijuana Stocks You’ll Want to Own for the Second Half of 2020
While all “next big thing” industries need time to mature (and cannabis is no different), the following three Marijuana Stocks are the names you’ll want to own for the second half of 2020: Green Thumb (CSE: GTII) (OTCQX: GTBIF) (FRA: R9U2), Innovative Industrial Properties (NYSE: IIPR) and Scotts Miracle-Gro (NYSE: SMG) (FRA: SCQA).
READ FULL MARIJUANA STOCKS ARTICLE
Revive Therapeutics (CSE: RVV) (OTCPK: RVVTF) (FRA: 31R) announced it has submitted today its Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (FDA) for a Phase 3 confirmatory study for Bucillamine as a potential treatment in COVID-19.
READ FULL REVIVE THERAPEUTICS ARTICLE
With U.S. Pot Stocks the Hot Theme of 2021, Here’s Why Red White & Bloom Could Be One of the Cannabis Sector’s Top Performers
Follow TCI on Social Media: Facebook | Instagram | Twitter | LinkedIn | Investor Group
Follow Psychedelic Profits on Social Media: Facebook | Twitter | LinkedIn | Investor Group
The Most Anticipated U.S. Weed IPO of 2020 is Finally Here
Get Your Copy of The Ultimate Cannabis Investing Guide
Join the Discussion in the TCI Investor Group
Read More:
Featured ArticlesCannabis Stock NewsCannabis Industry ArticlesTechnical Analysis ArticlesWatch Cannabis Stock Videos